ASH 2023 | Choosing between CPX-351 and FLAG-Ida in newly diagnosed and R/R AML
Keri Maher, DO, VCU Health, Richmond, VA, discusses an analysis of data from 142 patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML), treated with CPX-351 or FLAG-Ida. The analysis showed no significant difference in the composite complete response rate (CRc) and overall survival (OS) between these intensive chemotherapy regimens, meaning that physicians and institutions can choose between the two based on preference. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Sobi (Doptelet)
Board of Directors/Advisory committee: Bristol Myers Squibb
